Our Commitment to RSV Immunization
There is a shortage of the RSV antibody especially at the doses for infants over 11lbs. We encourage families with infants under 8months who would like Beyfortus to schedule a clinic visit as soon as possible.**
We are committed to the well-being of our community, especially when it comes to safeguarding against Respiratory Syncytial Virus (RSV). We are fully engaged with health officials and suppliers to make RSV immunizations available for children in our facility promptly. For now, the adult immunization is available at retail pharmacies. At the current time, only a single dose is recommended, and there are no recommendations for boosters.
Recommendations for Children
- All infants under 8 months of age during RSV season (October – March)
- Children 8-19 months of age who remain at high-risk of severe RSV disease through their second RSV season
High-risk children include those with chronic lung disease of prematurity, severe immunocompromise, cystic fibrosis exhibiting severe lung disease, and American Indian and Alaska Native children due to elevated rates of RSV-associated hospitalization.
*Please note, children must be under 8 months of age at the time of administration to be eligible
Importance of RSV Prevention
RSV is widespread and primarily affects the very young and the elderly. While it usually causes mild symptoms, it can lead to serious respiratory complications in vulnerable populations. The development of the RSV immunization and monoclonal antibody aims to shield these at-risk groups from potential complications.
Recommendations for Adults
For now, the adult vaccination is available at retail pharmacies. At the current time, only a single dose is recommended, and there are no recommendations for boosters.
Adults ages 60 and over are eligible to receive the RSV immunization. There is not a general recommendation for all adults in this age group to receive it, and shared decision making with your medical provider was advised.
The immunization is generally considered for those with advanced age and immunocompromising conditions as the risk of severe RSV infection is greater in this population. Additionally, individuals with chronic lung disease, coronary artery disease, congestive heart failure and diabetes may be at increased risk and should consider having the vaccination. If you do not have these conditions, you can choose to receive the immunization if you would like.
Receiving the RSV immunization with other vaccines is acceptable, however, this may reduce the antibody response to the RSV immunization or other immunizations. Additionally, the side effect profile may be greater if administered with other immunization.
The RSV immunization is new. It is generally felt to be a safe immunization at this time; however, monitoring for safety is ongoing.
If you would like a more in-depth discussion of your personal risk or side effect profile, please let us know via a portal message or call our office so we can schedule a telehealth visit.